newsfilter
← Latest News
GlobeNewswire·

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established